Merlin to raise US$125m

US life sciences VC has reached a first close on Merlin Nexus III, which will invest in late-stage private and public companies globally in the biotechnology, medical device, specialty pharmaceutical and molecular diagnostic field.

The firm has raised US$40m from investors such as Permal Capital Management and Capital E Group. It has a US$125m target.